T cell-derived IFNγ instructs ECM crosslinking by cardiac fibroblasts through LOXL3 in experimental cardiometabolic HFpEF
Ramona EmigiD, Zachary L. RobbeiD, Celina Kley, Sasha A. SmolgovskyiD, Abraham L. BayeriD, Joshua G. TraversiD, Robert M. BlantoniD, Timothy A. McKinseyiD, Lauren Deems BlackiD, Pilar AlcaideiD
Abstract
BackgroundHeart failure with preserved ejection fraction (HFpEF) is a major clinical challenge characterized by diastolic dysfunction. Left ventricular stiffening and inflammation are hallmarks of HFpEF, yet the contribution of extracellular matrix (ECM) stiffness and the immune-stromal mechanisms driving ECM stiffening in cardiometabolic HFpEF remain poorly understood. MethodsWe used the murine "2-hit model" of cardiometabolic HFpEF, in which the combination of high fat diet and hypertension induced by L-NAME causes diastolic dysfunction. We evaluated diastolic function by echocardiography and ECM mechanics by uniaxial tensile testing of decellularized cardiac tissue. Functional in vivo studies included genetic depletion of T cells, interferon-{gamma} (IFN{gamma}) knockout mice, and pharmacological lysyl oxidase inhibition. We combined co-cultures of CD4+ T cells and cardiac fibroblasts (CFB) with mechanical testing of cardiac ECM and molecular biology to elucidate cellular and molecular mechanisms. ResultsLeft ventricular ECM stiffness strongly correlated with impaired diastolic function in experimental cardiometabolic HFpEF. Cardiac CD4 T cell infiltration was required for ECM stiffening and upregulation of lysyl oxidase enzymes in CFB. CD4+ T cell-derived IFN{gamma} was both necessary and sufficient to induce LOXL3 in CFB, which increased ECM stiffness in vitro. Mechanistically, IFN{gamma} signaling activated hypoxia-inducible factor-1 (HIF1) in CFB, driving LOXL3 expression and subsequent collagen crosslinking. Genetic or pharmacologic disruption of this IFN{gamma}-HIF1-LOXL3 axis in vivo attenuated adverse ECM remodeling and improved diastolic function. ConclusionsCD4 T cells promote pathological ECM stiffening in cardiometabolic HFpEF through IFN{gamma}-mediated, LOXL3-dependent ECM crosslinking by CFB. Targeting this immune-stromal pathway may offer a novel therapeutic strategy for HFpEF.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- FWCI
- 9.99
- Field percentile
- top 2%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Bone marrow mesenchymal stromal cells mediate cellular inflammation in HFpEF
Kyle I. Mentkowski, I‐Hsiu Lee, … Matthias Nahrendorf·bioRxiv·Mar 28, 2025
- Mechanical loading reveals an intrinsic cardiomyocyte stiffness contribution to diastolic dysfunction in murine cardiometabolic disease
Johannes V. Janssens, Antonia J. A. Raaijmakers, … Lea M.D. Delbridge·The Journal of PhysiologyPeer-reviewed·Dec 1, 2024
- Time-Resolved Single-Cell Atlas Reveals Early Endothelial Activation and Stage-Dependent Immune-Stromal Communication in HFpEF
Jiantao Gong, Hannah Morgan, … Wei Chieh Huang·bioRxiv·Aug 11, 2026
- Free fatty acid receptor 4 (FFAR4) regulates cardiac oxylipin balance to promote inflammation resolution in a model of heart failure preserved ejection fraction secondary to metabolic syndrome
N. Zhang, K. A. Murphy, … T. O'Connell·bioRxiv·Apr 13, 2022
- Single-cell transcriptomics reveal distinctive patterns of fibroblast activation in murine heart failure with preserved ejection fraction
J. D. Lanzer, L. M. Wienecke, … F. Leuschner·bioRxiv·May 9, 2023
- Mechanistic Links Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Heart Failure with Preserved Ejection Fraction in a Mouse Model
Niveen Rweished, Yair Rokach, … Rabea Asleh·bioRxiv·Nov 2, 2025